These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 34144040)

  • 1. In vivo evaluation of anti-Leishmania activity of alkyltriazoles and alkylphosphocholines by oral route.
    Gontijo VS; Colombo FA; Ferreira Espuri P; Freitas PG; Nunes JB; Alves LB; Veloso MP; Alves RB; Freitas RP; Marques MJ
    Exp Parasitol; 2021; 226-227():108123. PubMed ID: 34144040
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LEISHMANICIDAL ACTIVITY in vivo OF A MILTEFOSINE DERIVATIVE IN Mesocricetus auratus.
    da Silva JC; Nunes JB; Gontijo VS; Malaquias LCC; de Freitas RP; Alves RB; Colombo FA; Laurenti MD; Marques MJ
    Acta Trop; 2020 Sep; 209():105539. PubMed ID: 32461110
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of liposomal buparvaquone in an experimental hamster model of Leishmania (L.) infantum chagasi.
    Reimão JQ; Colombo FA; Pereira-Chioccola VL; Tempone AG
    Exp Parasitol; 2012 Mar; 130(3):195-9. PubMed ID: 22281156
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Generation of luciferase-expressing Leishmania infantum chagasi and assessment of miltefosine efficacy in infected hamsters through bioimaging.
    Reimão JQ; Oliveira JC; Trinconi CT; Cotrim PC; Coelho AC; Uliana SR
    PLoS Negl Trop Dis; 2015 Feb; 9(2):e0003556. PubMed ID: 25679212
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Miltefosine-Lopinavir Combination Therapy Against
    Rebello KM; Andrade-Neto VV; Gomes CRB; de Souza MVN; Branquinha MH; Santos ALS; Torres-Santos EC; d'Avila-Levy CM
    Front Cell Infect Microbiol; 2019; 9():229. PubMed ID: 31316919
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tamoxifen as a potential antileishmanial agent: efficacy in the treatment of Leishmania braziliensis and Leishmania chagasi infections.
    Miguel DC; Zauli-Nascimento RC; Yokoyama-Yasunaka JK; Katz S; Barbiéri CL; Uliana SR
    J Antimicrob Chemother; 2009 Feb; 63(2):365-8. PubMed ID: 19095684
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and tolerability of oleylphosphocholine (OlPC) in a laboratory model of visceral leishmaniasis.
    Fortin A; Hendrickx S; Yardley V; Cos P; Jansen H; Maes L
    J Antimicrob Chemother; 2012 Nov; 67(11):2707-12. PubMed ID: 22782488
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Investigation of 8-methoxy-3-(4-nitrobenzoyl)-6-propyl-2H-chromen-2-one as a promising coumarin compound for the development of a new and orally effective antileishmanial agent.
    de Figueiredo Peloso E; Merli RJ; Espuri PF; Nunes JB; Colombo FA; Sierra EJT; de Paulo DC; Dos Santos MH; Carvalho DT; Marques MJ
    Mol Biol Rep; 2020 Nov; 47(11):8465-8474. PubMed ID: 33021720
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histamine H1-receptor antagonists against Leishmania (L.) infantum: an in vitro and in vivo evaluation using phosphatidylserine-liposomes.
    Pinto EG; da Costa-Silva TA; Tempone AG
    Acta Trop; 2014 Sep; 137():206-10. PubMed ID: 24905294
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of lapachol on treatment of cutaneous and visceral leishmaniasis.
    Araújo IAC; de Paula RC; Alves CL; Faria KF; Oliveira MM; Mendes GG; Dias EMFA; Ribeiro RR; Oliveira AB; Silva SMD
    Exp Parasitol; 2019 Apr; 199():67-73. PubMed ID: 30797783
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo antileishmanial activity and histopathological evaluation in Leishmania infantum infected hamsters after treatment with a furoxan derivative.
    de Almeida L; Passalacqua TG; Dutra LA; Fonseca JNVD; Nascimento RFQ; Imamura KB; de Andrade CR; Dos Santos JL; Graminha MAS
    Biomed Pharmacother; 2017 Nov; 95():536-547. PubMed ID: 28866421
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potentiation of the leishmanicidal activity of nelfinavir in combination with miltefosine or amphotericin B.
    Valdivieso E; Mejías F; Carrillo E; Sánchez C; Moreno J
    Int J Antimicrob Agents; 2018 Nov; 52(5):682-687. PubMed ID: 29969693
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular detection of infection homogeneity and impact of miltefosine treatment in a Syrian golden hamster model of Leishmania donovani and L. infantum visceral leishmaniasis.
    Eberhardt E; Mondelaers A; Hendrickx S; Van den Kerkhof M; Maes L; Caljon G
    Parasitol Res; 2016 Oct; 115(10):4061-70. PubMed ID: 27412759
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Finding of leishmanicidal activity of 14-hydroxylunularin in mice experimentally infected with Leishmania infantum.
    Serna ME; Maldonado M; Torres S; Schinini A; Lima AP; Pandolfi E; de Arias AR
    Parasitol Int; 2015 Oct; 64(5):295-8. PubMed ID: 25843766
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination therapy with nitazoxanide and amphotericin B, Glucantime®, miltefosine and sitamaquine against Leishmania (Leishmania) infantum intracellular amastigotes.
    Mesquita JT; Tempone AG; Reimão JQ
    Acta Trop; 2014 Feb; 130():112-6. PubMed ID: 24239532
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and pharmacodynamics of oleylphosphocholine in a hamster model of visceral leishmaniasis.
    Fortin A; Dorlo TP; Hendrickx S; Maes L
    J Antimicrob Chemother; 2016 Jul; 71(7):1892-8. PubMed ID: 27084920
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the in vitro and in vivo antileishmanial activity of a chloroquinolin derivative against Leishmania species capable of causing tegumentary and visceral leishmaniasis.
    Soyer TG; Mendonça DVC; Tavares GSV; Lage DP; Dias DS; Ribeiro PAF; Perin L; Ludolf F; Coelho VTS; Ferreira ACG; Neves PHAS; Matos GF; Chávez-Fumagalli MA; Coimbra ES; Pereira GR; Coelho EAF; Antinarelli LMR
    Exp Parasitol; 2019 Apr; 199():30-37. PubMed ID: 30817917
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Short- and long-term efficacy of hexadecylphosphocholine against established Leishmania infantum infection in BALB/c mice.
    Le Fichoux Y; Rousseau D; Ferrua B; Ruette S; Lelièvre A; Grousson D; Kubar J
    Antimicrob Agents Chemother; 1998 Mar; 42(3):654-8. PubMed ID: 9517947
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An effective in vitro and in vivo antileishmanial activity and mechanism of action of 8-hydroxyquinoline against Leishmania species causing visceral and tegumentary leishmaniasis.
    Costa Duarte M; dos Reis Lage LM; Lage DP; Mesquita JT; Salles BC; Lavorato SN; Menezes-Souza D; Roatt BM; Alves RJ; Tavares CA; Tempone AG; Coelho EA
    Vet Parasitol; 2016 Feb; 217():81-8. PubMed ID: 26827866
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antileishmanial activity of terpenylquinones on Leishmania infantum and their effects on Leishmania topoisomerase IB.
    Pérez-Pertejo Y; Escudero-Martínez JM; Reguera RM; Balaña-Fouce R; García PA; Jambrina PG; San Feliciano A; Castro MÁ
    Int J Parasitol Drugs Drug Resist; 2019 Dec; 11():70-79. PubMed ID: 31678841
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.